The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).

Lee S.  Rosen

Research Funding - Bayer (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Rgenix (Inst)

D. Ross  Camidge

Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; bio-thera; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Hengrui Pharmaceutical; Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; Puma Biotechnology; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics

Research Funding - Inivata (Inst)

Danny  Khalil

Consulting or Advisory Role - Abbvie; PsiOxus Therapeutics

Research Funding - Merck (Inst)

Patents, Royalties, Other Intellectual Property - Intellectual property interests related to CD40, nanotechnology, and in situ vaccination.

Thomas  Lillie

Employment - PsiOxus Therapeutics

Leadership - PsiOxus Therapeutics

Stock and Other Ownership Interests  - PsiOxus Therapeutics

Jo  Carter

Employment - PsiOxus Therapeutics

Stock and Other Ownership Interests  - PsiOxus Therapeutics

David  Krige

Employment - PsiOxus Therapeutics

Stock and Other Ownership Interests  - PsiOxus Therapeutics

Jessica  Davies

Employment - PsiOxus Therapeutics

Stock and Other Ownership Interests  - PsiOxus Therapeutics

David  Miles

No Relationships to Disclose

Minesh  Patel

Employment - PsiOxus Therapeutics

Stock and Other Ownership Interests  - PsiOxus Therapeutics

Vladimir  Evilevitch

Employment - PsiOxus Therapeutics

Stock and Other Ownership Interests  - PsiOxus Therapeutics

Isabel  Prieto González-Albo

Employment - PsiOxus Therapeutics

Brian  Champion

Employment - PsiOxus Therapeutics

Leadership - PsiOxus Therapeutics

Stock and Other Ownership Interests  - PsiOxus Therapeutics

Aung  Naing

Consulting or Advisory Role - CSL Behring (I); CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Pharma (I); Kymab; Novartis; OncoSec; Pharming NV (I); STCube Pharmaceuticals Inc.; Takeda (I)

Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc

Travel, Accommodations, Expenses - ARMO BioSciences